About Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)
Rigel Pharmaceuticals is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of various diseases, particularly those with unmet medical needs. The company specializes in molecular medicine, utilizing advanced technology to create targeted treatments for conditions such as cancer and immune disorders. Through its research initiatives, Rigel aims to deliver effective solutions that improve patient outcomes and enhance the quality of life for individuals facing challenging health issues. Read More
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.
Rigel Pharmaceuticals (RIGL) presents a strong GARP investment case with high growth, solid profitability, and a notably low valuation compared to its biotech peers.
Rigel Pharmaceuticals (RIGL) presents a strong value investment case with a very low P/E ratio, robust financial health, and high earnings growth potential.
Rigel Pharmaceuticals (RIGL) aligns with Mark Minervini's growth strategy, showing a strong technical uptrend supported by accelerating earnings and revenue momentum.
Discover Rigel Pharmaceuticals (RIGL), a GARP stock with explosive growth, a low P/E ratio, and strong financials, offering value in the biotech sector.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Rigel Pharmaceuticals shows explosive growth, strong cash flow, and high ROE, aligning with Louis Navellier's proven stock-picking system for growth investors.
